Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary
Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira